Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 315

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 315
---
 internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information.

(a)None.

(b)During the year ended December 31, 2024, no directors or “officers” (as defined in Rule 16a-1(f) under the Exchange Act) of our company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” and/or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not applicable.

95

Part III

Item 10.	Directors, Executive Officers and Corporate Governance.

Executive Officers and Directors 

The following table sets forth the persons who serve as our executive officers and directors, and their ages as of March 31, 2025: 

    Name
     
    Age
     
    Position(s)

    Executive Officers

    James Bianco, M.D.
     
    68
     
    Chief Executive Officer and Director 

    Dan Dearborn
     
    58
     
    Chief Financial Officer

    Non-Employee Directors

    James Manuso, Ph.D., MBA
     
    76
     
    Director and Chairman of the Board

    Alan List, M.D.
     
    70
     
    Director 

    George Ng
     
    51
     
    Director

    Robert E. Hoffman
     
    59
     
    Director

    Craig Tendler, M.D.
     
    66
     
    Director

Executive Officers

James Bianco, M.D. has served as our Chief Executive Officer and as a director since the completion of the Kintara Merger and for Legacy TuHURA since July 1, 2021. Dr. Bianco was also the founder, Chief Executive Officer and Chairman of Morphogenesis Biopharma, Inc., a biotechnology company, from its inception in November 2018 through its dissolution in January 2023, following the transfer of its assets to us. Dr. Bianco is a 30-year veteran of the biopharmaceutical industry.